207 related articles for article (PubMed ID: 25850006)
1. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients.
Zhang X; Hu Y; Zeng H; Li L; Zhao J; Zhao J; Liu F; Bao Y; Jia W
Cardiovasc Diabetol; 2015 Mar; 14():32. PubMed ID: 25850006
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus.
He X; Hu X; Ma X; Su H; Ying L; Peng J; Pan X; Bao Y; Zhou J; Jia W
Cardiovasc Diabetol; 2017 Jun; 16(1):77. PubMed ID: 28619026
[TBL] [Abstract][Full Text] [Related]
3. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes.
Xiao Y; Liu L; Xu A; Zhou P; Long Z; Tu Y; Chen X; Tang W; Huang G; Zhou Z
Cardiovasc Diabetol; 2015 Jun; 14():72. PubMed ID: 26047614
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes.
Yafei S; Elsewy F; Youssef E; Ayman M; El-Shafei M
Diabetes Metab Syndr; 2019; 13(1):882-888. PubMed ID: 30641825
[TBL] [Abstract][Full Text] [Related]
5. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors.
Chow WS; Xu A; Woo YC; Tso AW; Cheung SC; Fong CH; Tse HF; Chau MT; Cheung BM; Lam KS
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2454-9. PubMed ID: 23887638
[TBL] [Abstract][Full Text] [Related]
6. The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes.
He X; Su J; Ma X; Lu W; Zhu W; Wang Y; Bao Y; Zhou J
Cardiovasc Diabetol; 2020 Mar; 19(1):40. PubMed ID: 32222153
[TBL] [Abstract][Full Text] [Related]
7. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease.
Shen Y; Ma X; Zhou J; Pan X; Hao Y; Zhou M; Lu Z; Gao M; Bao Y; Jia W
Cardiovasc Diabetol; 2013 Aug; 12():124. PubMed ID: 23981342
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events.
Wu L; Qian L; Zhang L; Zhang J; Zhou J; Li Y; Hou X; Fang Q; Li H; Jia W
J Am Heart Assoc; 2020 Jun; 9(11):e015226. PubMed ID: 32431189
[TBL] [Abstract][Full Text] [Related]
10. Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and cardiovascular events: Multi-Ethnic Study of Atherosclerosis.
Ong KL; Campbell S; Wu BJ; McClelland RL; Kokkinos J; Szklo M; Polak JF; Allison MA; Rye KA
Atherosclerosis; 2019 Aug; 287():46-53. PubMed ID: 31212234
[TBL] [Abstract][Full Text] [Related]
11. Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects.
Jin QR; Bando Y; Miyawaki K; Shikama Y; Kosugi C; Aki N; Funaki M; Noji S
J Med Invest; 2014; 61(1-2):28-34. PubMed ID: 24705745
[TBL] [Abstract][Full Text] [Related]
12. Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes.
Eto K; Tumenbayar B; Nagashima S; Tazoe F; Miyamoto M; Takahashi M; Ando A; Okada K; Yagyu H; Ishibashi S
Diabetes Res Clin Pract; 2010 Jul; 89(1):52-7. PubMed ID: 20452080
[TBL] [Abstract][Full Text] [Related]
13. Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus.
Lee CH; Woo YC; Chow WS; Cheung CYY; Fong CHY; Yuen MMA; Xu A; Tse HF; Lam KSL
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588089
[TBL] [Abstract][Full Text] [Related]
14. Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes.
Jin S; Xia N; Han L
BMJ Open Diabetes Res Care; 2021 Mar; 9(1):. PubMed ID: 33789910
[TBL] [Abstract][Full Text] [Related]
15. Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients.
Esteghamati A; Momeni A; Abdollahi A; Khandan A; Afarideh M; Noshad S; Nakhjavani M
Ann Endocrinol (Paris); 2016 Oct; 77(5):586-592. PubMed ID: 27106505
[TBL] [Abstract][Full Text] [Related]
16. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.
Lee CH; Hui EY; Woo YC; Yeung CY; Chow WS; Yuen MM; Fong CH; Xu A; Lam KS
J Clin Endocrinol Metab; 2015 Apr; 100(4):1368-75. PubMed ID: 25625802
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
[TBL] [Abstract][Full Text] [Related]
18. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.
Cuevas-Ramos D; Almeda-Valdes P; Gómez-Pérez FJ; Meza-Arana CE; Cruz-Bautista I; Arellano-Campos O; Navarrete-López M; Aguilar-Salinas CA
Eur J Endocrinol; 2010 Sep; 163(3):469-77. PubMed ID: 20566587
[TBL] [Abstract][Full Text] [Related]
19. Associations between FGF21, osteonectin and bone turnover markers in type 2 diabetic patients with albuminuria.
Xu L; Niu M; Yu W; Xia W; Gong F; Wang O
J Diabetes Complications; 2017 Mar; 31(3):583-588. PubMed ID: 27916484
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes.
Hu J; Liu Z; Tong Y; Mei Z; Xu A; Zhou P; Chen X; Tang W; Zhou Z; Xiao Y
Front Endocrinol (Lausanne); 2020; 11():282. PubMed ID: 32528406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
